Alto Neuroscience (ANRO) details 7,189-share director stock option grant

Rhea-AI Filing Summary

Alto Neuroscience director reports new stock option grant. A board member of Alto Neuroscience, Inc. filed a Form 4 reporting receipt of a stock option covering 7,189 shares of common stock on 01/02/2026.

The option was granted under the company’s Non-Employee Director Compensation Policy in lieu of cash retainer fees of $85,000. Vesting is scheduled in four installments during 2026: 1,797 shares on March 31, 1,797 shares on June 30, 1,798 shares on September 30, and 1,797 shares on December 31, contingent on the director’s continuous service through each vesting date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cox Christopher Nixon

(Last) (First) (Middle)

C/O ALTO NEUROSCIENCE, INC.

650 CASTRO STREET, SUITE 450

(Street)

MOUNTAIN VIEW CA 94041

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Alto Neuroscience, Inc. [ ANRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$16.59	01/02/2026		A		7,189		(1)	01/01/2036	Common Stock	7,189	$11.82(2)	7,189	D

Explanation of Responses:

1. 1,797 shares underlying the option shall vest on March 31, 2026, 1,797 shares underlying the option shall vest on June 30, 2026, 1,798 shares underlying the option shall vest on September 30, 2026 and 1,797 shares underlying the option shall vest on December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date.

2. This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $85,000.

Remarks:

	/s/ Erin R. McQuade, Attorney-in-Fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Alto Neuroscience (ANRO) report in this Form 4?

A director of Alto Neuroscience, Inc. reported receiving a stock option for 7,189 shares of common stock, with a transaction date of 01/02/2026.

Who is the reporting person and what is their relationship to Alto Neuroscience (ANRO)?

The reporting person is identified as a Director of Alto Neuroscience, Inc., and the filing is made by one reporting person.

What are the vesting terms of the Alto Neuroscience director stock option?

The 7,189-share option vests in four tranches in 2026: 1,797 shares on March 31, 1,797 shares on June 30, 1,798 shares on September 30, and 1,797 shares on December 31, subject to continued service.

Why was the Alto Neuroscience director granted this stock option?

The filing states the option was issued under the company’s Non-Employee Director Compensation Policy in lieu of $85,000 in retainer fees.

What is the exercise price of the reported Alto Neuroscience stock option?

The derivative table lists a stock option (right to buy) with a conversion or exercise price of $16.59 per share.

When does the Alto Neuroscience director stock option expire?

The option carries an expiration date of 01/01/2036, as shown in the derivative securities table.

Is the Alto Neuroscience Form 4 filed under a Rule 10b5-1 trading plan?

The form includes a checkbox for indicating Rule 10b5-1(c) plans; the excerpt does not show that box as marked, and the transaction is presented simply as a director compensation grant.